LXRXLexicon Pharmaceuticals, Inc.
Price
+40%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, growth steady, the market undecided.
We are a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA® (sotagliflozin): The FDA has separately provided feedback that a third-party-funded, investigator-initiated study of sotagliflozin appears to be of adequate design and employs sufficient data collection methods to provide viable evidence of the incidence of diabetic ketoacidosis, or DKA, with adequate safety data, prior to its completion, to support review of a resubmission of the NDA.
In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Lexicon Pharmaceuticals, Inc. (LXRX) reported revenue of $692K in Q2 2026 (quarter ended Jun 30, 2026), down 98% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $32M. For the full year FY2025, revenue was $50M (+60% year on year) and net income −$50M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- May 6, 2026Loan and Security Agreement On May 4, 2026, Lexicon Pharmaceuticals, Inc. (“Lexicon”) and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (“Hercules”) that provides up to $100 million in borrowing capacity (the “Hercules Term Loans”) available in …Material agreement entered · Form 8-K
- Apr 30, 2026Unregistered Sale of Equity Securities On April 30, 2026, each outstanding share of our Series B Convertible Preferred Stock, par value $0.01 per share (the “Preferred Stock”), was converted (the “conversion”) into 50 shares of our common stock, par value $0.001 per share (the “Common Stock”). 408,434.7 shares of …Material agreement entered · Form 8-K
- Feb 2, 2026Underwriting Agreement On January 29, 2026, Lexicon Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC (“Jefferies”) and Piper Sandler & Co. (“Piper Sandler”), as representatives of the several underwriters named therein (the “Underwriters”) …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.